NEWSAttention Business/Financial Editors:
MedMira and AHD Achieve First Sales Win in Indonesia as a Result of South East Asia Market Expansion
HALIFAX, April 21 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR,NASDAQ: MMIRF), a developer and marketer of rapid diagnostic technology andsolutions, and US-based sales and marketing partner American HealthDiagnostics LLC (AHD), announced today that their South East Asia marketexpansion initiatives have resulted in product sales in Indonesia. Asannounced in August 2008, MedMira and AHD are working together to break in tothis developing market and sell at least one million rapid HIV tests in theSouth East Asia region over the next year. Local distributors Lauw Management USA and PT Sehat Selaras Sejahtera,along with MedMira and AHD pursued and received regulatory approval inIndonesia for MedMira's MiraWell Rapid HIV Test (MiraWell HIV). In addition toregulatory approval, the sales and marketing registrations required to sellthe product in this market has also been completed. "We have converted our Southeast Asia market expansion into concretesales opportunities in Indonesia. Working with our partners, AHD, LauwManagement USA, and PT Sehat Selaras Sejahtera, we were able to move throughthe evaluation and regulatory process smoothly in order to realize our firstsales in the region," said Hermes Chan, president and CEO, MedMira Inc. "Thisis the first in a series of initiatives included in our market developmentplan for the region. Working with our strategic partners in South East Asia wewill sell our competitively priced, quality diagnostics to other countries inthe region." AHD, Lauw Management USA, and PT Sehat Selaras Sejahtera will use thefirst shipment of MiraWell HIV to target both private and public sectorcustomers. With a comprehensive sales and marketing campaign slated to beginin May, follow-on orders are anticipated in the coming months. "We are very excited about bringing this product to customers inIndonesia," said Brad Adams, Executive Vice President of AHD. "We are well onour way to establishing MiraWell HIV as a brand known for quality andperformance and fully developing the sales opportunities that exist inIndonesia for this product." About American Health Diagnostics American Health Diagnostics brings innovations to life through aproprietary market readiness process and proven distribution managementnetwork. The AHD market readiness and distribution management system has beenutilized to introduce MedMira's Reveal(R) Rapid HIV-1 Antibody Test, themarket's fastest FDA approved HIV test, and ThyroTec's ThyroTest(TM), thefirst ever FDA approved and CLIA Waived rapid hypothyroid diagnostic screeningdevice. www.ahpartners.com About MedMira MedMira is a leading developer and manufacturer of flow-through rapiddiagnostics. The company's tests provide hospitals, labs, clinics andindividuals with reliable, rapid diagnosis for diseases such as HIV andhepatitis C in just three minutes. The company's tests are sold under theReveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in globalmarkets. MedMira's rapid HIV test is the only one in the world to achieveregulatory approvals in Canada, the United States, China and the EuropeanUnion. MedMira's corporate offices and manufacturing facilities are located inHalifax, Nova Scotia, Canada. For more information visit MedMira's website atwww.medmira.com. This news release contains forward-looking statements, which involve riskand uncertainties and reflect the company's current expectation regardingfuture events. Actual events could materially differ from those projectedherein and depend on a number of factors including, but not limited to,changing market conditions, successful and timely completion of clinicalstudies, uncertainties related to the regulatory approval process,establishment of corporate alliances and other risks detailed from time totime in the company quarterly filings. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement. %SEDAR: 00013053E
For further information: Andrea Young, Corporate Communications,MedMira, (902) 450-1588, ayoung@medmira.com